Creo Medical Says First Patient Treated With Speedboat Device
Creo Medical Group PLC announced the first clinical use of its Speedboat device on 22 June. The patient, suffering with a large pre-cancerous lesion in the gastrointestinal tract, was treated using Creo’s Speedboat device powered by Creo’s CROMA electrosurgery advanced energy platform at St. Mark’s Hospital in London.
This first treatment of a patient using a product from Creo’s endoscopic pipeline is a significant landmark for the firm and puts them in a strong position to become a leader in this growing billion dollar market. Creo Medical is developing a range of surgical devices that can dissect tissue while using microwaves to staunch the blood flow. These are designed to be used with an endoscope to reduce the need for open surgery.
Mewburn partner Richard Johnson works closely with Creo Medical in relation to the building and defending of their European patent portfolio.